Examples of trials evaluating MRD to guide treatment. Treatment decisions with MRD may be broadly divided into 2 categories: (A) following initial therapy to guide treatment intensification or consolidation in patients with MRD positive disease or (B) in patients on maintenance therapy, to guide discontinuation of treatment. Some trials are also examining “early” initiation of therapy with the appearance of MRD-positive disease. D, dexamethasone; isa, isatuximab; K, carfilzomib; maint, maintenance; PD, progressive disease; PREDATOR, Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma; R, lenalidomide; RADAR, Risk-Adapted Therapy Directed According to Response; REMNANT, Relapse from MRD Negativity as Indication for Treatment; V, bortezomib.